Genetic Technologies Limited

For the year ended June 30, 2023, Genetic Technologies reported cash receipts of A$8.8 million, up 29% versus the prior year. Gross margin was A$4.2 million, or 47%, and cash at bank was A$7.9 million. In quarter four, the company delivered A$2.1 million in cash receipts, and geneType commercial samples rose 250% quarter over quarter. Management said the business believes it can reach a pathway to profitability by the middle of FY2025, driven by growth in geneType, EasyDNA, and Affinity DNA, plus larger U.S. payer and distributor relationships.

Simon Morriss framed the company as transitioning from a long R&D phase into commercialization and then profitability, with a clear focus on revenue generation. He emphasized the company’s multi-brand strategy, global portfolio, and clinical collaborations, and repeatedly pointed to geneType as the core growth engine. His tone was upbeat and execution-focused, with a lot of emphasis on upcoming milestones over the next 18 months and on building credibility through publications, guidelines submissions, and clinical utility evidence.

Tony Di Pietro focused on integration and control as the company has folded in two acquired businesses and expanded into more geographies. He said the acquisitions increased direct-to-consumer exposure and brought European operations, while systems, reporting lines, and efficiencies have now been embedded. On risk management, he said cybersecurity has been strengthened, including improved processes for the new businesses and migration to Office 365, with Melbourne moving through a similar upgrade.

Analysts pressed management on the key growth drivers, and Simon said the priorities are baseline direct-to-consumer businesses, geneType growth, the hereditary breast and ovarian cancer test, and securing a meaningful U.S. payer or distributor. On payer progress, Carl Stubbings said the company is building evidence through a pilot and expects that to move existing conversations forward. Questions on ESG drew a firm response that it is not a box-ticking exercise; Simon said the company has completed its baseline report and is now defining concrete actions on board composition, conduct policies, and culture.